Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


bluebird bio to Present at Jefferies Cell Therapy Virtual Summit


Business Wire | Sep 28, 2020 08:00AM EDT

bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

Sep. 28, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 28, 2020--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET.

To access the live webcast of bluebird bio's presentation, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we're developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we're working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We're putting our care and expertise to work across a spectrum of disorders, including cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using three gene therapy technologies: gene addition; cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash., Durham, N.C., and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005373/en/

CONTACT: Investors & Media

CONTACT: Investors: Ingrid Goldberg, 857-217-0490 igoldberg@bluebirdbio.com OR Elizabeth Pingpank, 617-914-8736 epingpank@bluebirdbio.com

CONTACT: Media: Jenn Snyder, 617-448-0281 jsnyder@bluebirdbio.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC